InvestorsHub Logo
Followers 32
Posts 2810
Boards Moderated 3
Alias Born 10/24/2015

Re: None

Saturday, 11/16/2019 12:59:49 PM

Saturday, November 16, 2019 12:59:49 PM

Post# of 76
The company has inked an agreement with Noile-Immune Biotech for rights to develop certain CAR-T therapies using Noile's PRIME (PRoliferation-Inducing and Migration-Enhancing) tech secreting both IL-7 and CCL19.

Here is some preclinical data https://www.nature.com/articles/nbt.4086
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AUTL News